AI assistant
Hikal Ltd. Capital/Financing Update 2021
61437_rns_2021-05-05_c453ed15-4d18-4c0c-a67b-6c23ba4b1739.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Date: May 5, 2021
The Secretary, Listing Department BSE Ltd P J Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 524735
The Manager, Listing Department National Stock Exchange of India Ltd Exchange Plaza, Bandra-Kurla Complex, Bandra Mumbai - 400 051. Symbol: HIKAL
Dear Sir/Madam,
Sub.: 10-year multi-product contract with a leading global pharmaceutical innovator company
Ref.: Iniimation under Regulation 30 and other applicabJe regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Please find enclosed herewith, a copy of the press release regarding long term contract entered into by the Company with a leading global pharmaceutical innovator company.
Please treat this as an intimation under Regulation 30 of SEBI LODR.
Kindly take the above on your record.
For Hikal Limited,
Rajasekhar Reddy Company Secretary & Compliance Officer
Hikal Ltd.
Admin. Office: Great Eastern Chambers. 6th Floor. Sector 11. CBD Belapur, Navi Mumbai - 400 614, India Tel.: +91-22-3097 3100 Fax: +91-22-2757 4277 Regd. Office : 717, Maker Chamber - 5, Nariman Point, Mumbai - 400 021, India. Tel. : +91-22-3926 7100, +91-22-6277 0477. Fax: +91-22-2283 3913 www.hikal.com [email protected] CIN: l24200MH1988PTC048028
PRESS RELEASE
Hikal signs a 10-year multi product deal with a leading global pharmaceutical innovator company
Mumbai, 5 th May, 2021: Hikal Ltd., a preferred long-term partner for leading global life sciences companies, today announced that they have signed multi-year contract with a leading global pharmaceutical company. This contract entails the development and supply of a portfolio of niche APIs over a period of 10 years. The development will start this year and commercial supplies will commence post successful development and plant commercialisation estimated to be in FY 2024 onwards. With this deal, Hikal is entering into a niche area of chemistry and products thereby bolstering its Animal Health vertical. Hikal and its customer will be jointly investing at its Panoli, Gujarat site to setup a multipurpose manufacturing asset for manufacturing of these API's.
Commenting on this development, Mr. Sameer Hiremath, CEO, Hikal said, "We are very excited to be working with one of the leading global innovator pharmaceutical companies who have entrusted us to supply them with a strategic portfolio of APIs. We worked very closely with our customer to provide them a sustainable long-term competitive solution for their product portfolio from early-stage development to commercial supply. Hikal and our customer will be partnering in setting up a manufacturing facility to maintain security of supplies for the next ten years. We are seeing multiple opportunities from several new and existing customers who are looking to diversify and de-risk their existing supply chain."
About Hikal Limited
Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal's R&D facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).
Safe Harbor Statement
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.
| Company: | Investor Relations Advisors: |
|---|---|
| Hikal Limited | Strategic Growth Advisors Pvt. Ltd. |
| CIN: L24200MH1988PTC048028 | CIN: U74140MH2010PTC204285 |
| Mr. Anish Swadi | Mr. Jigar Kavaiya |
| [email protected] | [email protected] |
| +91 9920602034 | |
| www.hikal.com | www.sgapl.net |